NATCO Pharma Limited (BOM:524816)
India · Delayed Price · Currency is INR 884.95
+0.65 (0.07%)
At close: Sep 19, 2025
NATCO Pharma Employees
NATCO Pharma had 4,199 employees as of March 31, 2025. The number of employees increased by 183 or 4.56% compared to the previous year.
Employees
4,199
Change (1Y)
183
Growth (1Y)
4.56%
Revenue / Employee
10.47M INR
Profits / Employee
4.04M INR
Market Cap
158.38B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4,199 | 183 | 4.56% |
| Mar 31, 2024 | 4,016 | 70 | 1.77% |
| Mar 31, 2023 | 3,946 | -79 | -1.96% |
| Mar 31, 2022 | 4,025 | -1,021 | -20.23% |
| Mar 31, 2021 | 5,046 | 20 | 0.40% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Reliance Industries | 403,303 |
| HDFC Bank | 214,521 |
| Bharti Airtel | 13,593 |
| Tata Consultancy Services | 607,979 |
| ICICI Bank | 182,665 |
| State Bank of India | 236,226 |
| Infosys | 323,578 |
| Bajaj Finance | 64,092 |
NATCO Pharma News
- 1 day ago - Natco Pharma receives US FDA’s VAI classification for Hyderabad unit - Business Upturn
- 9 days ago - Natco Pharma moves closer to Adcock Ingram acquisition with shareholder vote set for October - Business Upturn
- 4 weeks ago - Natco Pharma launches generic Bosentan tablets for oral suspension in the US with 180-day exclusivity - Business Upturn
- 4 weeks ago - Lupin launches Bosentan Tablets for Oral Suspension in US with 180-day exclusivity - Business Upturn
- 5 weeks ago - Brokerage recommendations for August 14: Muthoot Finance, Va Tech Wabag, JSPL, VMM, BPCL, Devyani, Apollo Hospitals, HDFC Life, Infosys, Brainbees, United Spirits, Motherson, Jubilant Food, PI Industries, Natco Pharma, ONGC in focus - Business Upturn
- 5 weeks ago - Natco Pharma board declares interim dividend of Rs 2 per share for FY26 - Business Upturn
- 5 weeks ago - NATCO Pharma Q1 Results: Revenue slips marginally to Rs 1,390.6 crore, net profit falls 28.1% YoY - Business Upturn
- 2 months ago - Natco Pharma gets EIR from USFDA for Hyderabad API facility - Business Upturn